GE HealthCare Technologies Inc. (GEHC) Stock: Price, Forecast & Analyst Target
GE HealthCare Technologies Inc. (GEHC) — MoonshotScore 74/100 (Strong band), calculated Nov 18, 2026. Price $81.89 (-2.12%), as of the Nov 19, 2026 trading session; market cap $37.0B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
GE HealthCare Technologies Inc. · GEHC · NASDAQ · Healthcare · Medical - Devices
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered): GE HealthCare sells diagnostic imaging systems, ultrasound platforms, bedside care equipment, services, digital tools, and the agents clinicians administer to make scans more informative. Its breadth matters only if improved supply execution and longer-cycle orders produce steadier profit and cash while debt remains far above cash.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · GE HealthCare Technologies (GEHC)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $5.51B (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 7 of the last 8 reports
- expected results Feb 3, 2027
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 73 | Strong | |
| 73 | Strong | |
| 77 | Strong | |
| 77 | Strong | |
| 74 | Strong | |
| 74 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $81.89 | |
| Change on the day | -2.12% | |
| 52-week range | $58.75–$89.77 | |
| Market capitalisation | $37.0B | — |
| Price / earnings (trailing) | 17.27 | |
| Shares traded on the day | 2.84M | |
| Beta (volatility vs the S&P 500) | 0.77 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for GE HealthCare Technologies (GEHC): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 12, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is GE HealthCare Technologies (GEHC), and what does it report?
Short answer · as of
GE HealthCare is not merely a scanner manufacturer. It supplies imaging and ultrasound equipment, patient monitoring and anesthesia products, diagnostic pharmaceuticals, consumables, services, and digital platforms to hospitals, clinicians, radiology practices, and nuclear medicine providers.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Reported company results therefore combine capital-equipment demand, service and consumable activity, and scan-linked pharmaceutical use. Imaging contributes the largest amount among the disclosed segment revenues, while Patient Care Solutions and Pharmaceutical Diagnostics add materially different demand patterns.
What do the latest results show for GE HealthCare Technologies (GEHC)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $5.51B.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Revenue, gross profit, operating profit, and net income all advanced from the preceding reported period and from the comparable period. The latest reported revenue and earnings also cleared estimates, following a report in which revenue exceeded expectations while earnings fell short.
Management expects easing supply constraints to support sales and margins, with execution focused on volume and margin recovery. It also says orders for products with longer conversion cycles should contribute more meaningfully later, making that conversion an outlook claim that still requires confirmation in reported revenue and cash flow.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $5.51B | $614M | $1.36 (diluted) |
| Q2 FY2026 | $5.29B | $573M | $1.24 (diluted) |
| Q1 FY2026 | $5.13B | $389M | $0.85 (diluted) |
| Q4 FY2025 | $5.70B | $589M | $1.29 (diluted) |
What are the financial strengths and risks for GE HealthCare Technologies (GEHC)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
Revenue has expanded across the annual series, while net income recovered from its recent low but remains below earlier levels. Most reported periods produced positive operating cash flow, yet the latest period swung negative and capital spending deepened the cash outflow.
Cash has fallen markedly across the reported window, and debt remains far above cash. Current assets only narrowly cover current liabilities, while the more liquid asset measure falls short; repeated cash outflows would therefore tighten financial flexibility.
Supply disruption is especially consequential here because it can restrain equipment volume and margins while long sales cycles postpone revenue recognition. That combination can leave improving accounting profit disconnected from cash generation.
What should you watch next at GE HealthCare Technologies (GEHC)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
The next earnings release needs to extend the recent gains in revenue and operating profit while showing that anticipated supply improvement is reaching volume and margins. Positive operating cash flow would strengthen that signal; another divergence between profit and cash would weaken it.
Cash relative to debt deserves continued attention, as does the conversion of longer-cycle orders into revenue. Consensus estimates assume continued revenue and earnings growth across future annual periods, so stalled conversion or continued cash depletion would challenge the expected trajectory.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does GE HealthCare Technologies compare with its peers?
Short answer
GE HealthCare Technologies's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered).
GE HealthCare participates across the clinical workflow: it sells scanners and ultrasound systems, equips bedside care, and supplies contrast media and molecular imaging agents used during diagnostic procedures. That creates exposure to hospital equipment purchases, service activity, consumable use, and procedure-linked pharmaceutical demand.
Imaging dominates the disclosed segment mix, but Patient Care Solutions and Pharmaceutical Diagnostics distinguish the company from a focused scanner or monitoring peer. The breadth reduces reliance on a narrow product category while tying execution to hospital budgets, procedure activity, manufacturing supply, and complex sales cycles.
| Company | Price | Market value | Score |
|---|---|---|---|
| $403.60 Nov 18, 2026 | $46.1B | 96 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $320.00 Nov 19, 2026 | $12.6B | 92 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $29.83 Nov 19, 2026 | $12.5B | 84 5-pillar Nov 18, 2026 | |
| $175.34 Nov 19, 2026 | $49.4B | 83 5-pillar Nov 18, 2026 | |
| $163.96 Nov 18, 2026 | $11.6B | 83 5-pillar Nov 18, 2026 | |
| $74.52 Nov 19, 2026 | $35.8B | 80 5-pillar Nov 18, 2026 | |
| $101.47 Nov 19, 2026 | $19.2B | 79 5-pillar Nov 18, 2026 | |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| GE HealthCare Technologies (GEHC) — this page | $81.89 | $37.0B | 74 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $67.00 – $95.00
- Consensus target
- $81.22
- Median target
- $80.00
Consensus record · Captured .
Measured against a quoted price of $81.89 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026
- Transactions
- 23
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 0
- Other transactions
- 23
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GEHC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GEHC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about GE HealthCare Technologies (GEHC)?
What Investors Ask About GE HealthCare Technologies (GEHC) — Healthcare
Research dated 2026-09-12 (results through Q2 FY2026; Q3 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do GE HealthCare imaging systems and Pharmaceutical Diagnostics fit together?
The company sells imaging equipment as well as contrast media and molecular imaging agents administered for diagnostic procedures. Revenue therefore reflects equipment placement and scan-related pharmaceutical demand rather than scanner sales alone.
Why can GE HealthCare orders take time to appear as revenue?
Management says some products have longer sales conversion cycles, so booked demand may not contribute meaningfully to revenue until later. Reported sales and cash generation must confirm that those orders are converting.
Is Imaging the largest disclosed GE HealthCare segment?
Imaging contributes the most revenue among the segments in the disclosed breakdown. Patient Care Solutions and Pharmaceutical Diagnostics remain meaningful because they connect GE HealthCare to bedside care and procedure-linked agents beyond large imaging equipment.
Why should investors watch GE HealthCare cash conversion?
Profit improved in the latest reported period, but operating cash flow turned negative and cash continued to decline. Sustained positive cash generation would show that better operating results are translating into balance-sheet capacity.
What is the GEHC stock price today?
The last price recorded for GE HealthCare Technologies Inc. (GEHC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GEHC price target?
The analyst consensus price target for GE HealthCare Technologies Inc. (GEHC), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold GEHC
Funds in our ETF coverage that list GEHC among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 9.74% |